mumps infectivity mumps transmission
Conditions
Interventions
None listed
Sponsors
RIVM
Eligibility
Age
12 Years to 99 Years
Inclusion criteria
Inclusion criteria: Transmission part: * Elegibilty of the contacts of an index case depends on the index case. The contacts of an index case are only eligible for participation when the index case has a laboratory confirmed mumps virus infection and when the index case belongs to a suitable social network. * The suitability of the network will be assessed by the research team. A suitable network is one with a high chance of mumps transmission occurring. This will depend on the age and residential situation of the network. The research team will use descriptive epidemiological information from mumps transmission networks that occurred in 2010 and 2011. * >= 16 years of age * Inclusion of first ring contacts should be within 10 days of the first symptoms of mumps disease of the index case;Cellular immunity part: • A mumps case is eligible for participation in the cellular immunity study as case when mumps virus infection has been laboratory confirmed, and when he/she is >=18 yrs of age. • A control for the cellular immunity study is a person who has no evidence of a recent mumps infections, e.g. contacts from the transmission study with a negative clinical history and absence of a serological response, has been vaccinated against mumps in the past, and he/she is >=18 yrs of age.
Exclusion criteria
Exclusion criteria: Transmission part: - having mumps at the time of inclusion, or ever have had mumps in the past. Cellular immunity: - be or have been under immunosuppressive medical treatment, like cytostatics and prednisolons that might interfere with the results of the study (within the previous 3 months) - have any known primary or secondary immunodeficiency, or bleeding disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of transmission events Viral excretion patterns and immuun responses among symptomatic and asymptomatic infected individuals | — |
Secondary
| Measure | Time frame |
|---|---|
| To gain insight into cross-reactive potential of mumps specific cellular immune mechanisms to circulating vaccine type and non-vaccine type mumps strains | — |
Countries
Netherlands
Outcome results
None listed